Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

14.8%

4 terminated out of 27 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

7%

2 trials in Phase 3/4

Results Transparency

56%

9 of 16 completed with results

Key Signals

9 with results80% success

Data Visualizations

Phase Distribution

21Total
Not Applicable (4)
Early P 1 (1)
P 1 (2)
P 2 (12)
P 3 (1)
P 4 (1)

Trial Status

Completed16
Recruiting4
Terminated4
Unknown2
Active Not Recruiting1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (27)

Showing 20 of 20 trials
NCT01042379Phase 2Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT02004834Phase 4Active Not RecruitingPrimary

Levobupivacaine and Lidocaine for Paravertebral Block Causes Greater Hemodynamic Oscillations Than Levobupivacaine

NCT07209020Not ApplicableRecruitingPrimary

HealiAid Collagen Wound Dressing in Patients Undergoing Breast Tumor Surgery

NCT05582499Phase 2Recruiting

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

NCT04132960Phase 2CompletedPrimary

Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

NCT06805812Recruiting

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

NCT02187991Phase 2Completed

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

NCT00626106Phase 2Completed

QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

NCT05976620CompletedPrimary

Clinical Study of 18F-FAPI-RGD in Breast Tumors

NCT05584644Completed

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

NCT00639171CompletedPrimary

Evaluate the Use of the Magnetic Resonance Spectroscopy in Determining if the Breast Tumor is Benign or Malignant

NCT01980823Early Phase 1Completed

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

NCT00807859Phase 1Completed

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

NCT05133674Phase 2Unknown

Therapeutic Dose Monitoring (TDM) of Tamoxifen

NCT02296801Phase 2Completed

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

NCT02891681Not ApplicableCompleted

Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment

NCT01807754Completed

Simulated Screening Study for Breast Imaging

NCT01118624Phase 2Completed

Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer

NCT02472353Phase 2Terminated

Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer

NCT02225470Phase 3Completed

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Scroll to load more

Research Network

Activity Timeline